FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
October 19, 2015
Articles coincide with start of investor awareness, increased marketing efforts and direct to pharmacist advertising
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, today confirmed coverage of the Company by the Toronto-based The Globe and Mail newspaper and Canadian technology expert, Electronic Products & Technology magazine.
The Globe and Mail published their article entitled "Handheld heart monitoring for when the doctor is out; Toronto-based CardioComm is building a global market for its portable ECG devices" on Friday October 16, 2015, in the newspaper's Report On Business "Global Innovation – Health Care" section.
In the article, the Company's history was reviewed with an emphasis on their HeartCheck™ ECG PEN device which is cleared for sale as a consumer (Class II) Medical Device in Canada, the USA, Europe, Australia and China. Whether there is a need to address limited access to a physician because of where people live, or a person wishes to be proactive in keeping on top of their health, there is a need for health care providers to have access to portable and more affordable ECG monitoring technologies in countries such as India, Africa and Asia. Awareness for the CardioComm Solutions HeartCheck™ ECG devices has been increasing. According to the Company at least 796 Shoppers Drug Mart pharmacies now carry the HeartCheck™ ECG PEN and international interest has resulted in sales to customers in 29 countries. Already a disruptive product in the medical markets, the Company confirmed plans to offer Bluetooth enabled ECG monitoring devices that will work through Smartphone applications which has appeal to mobile carriers internationally and at home.
The Company was also profiled by EP&T magazine in an article entitled "Wellness products versus medical devices. Toronto-based CardioComm underscores the importance of collaboration with emerging sector". The article highlighted the issues related to:
- consumer use of poorly regulated wellness devices to monitor health status;
- the need for access to new affordable, consumer friendly medical devices that are better controlled in their manufacturing and their accuracy when used to assess health status; and
- the importance for Canadian companies to collaborate when working to bring new medical technologies to global markets.
The Company confirms that requests for business collaborations and HeartCheck™ device sales opportunities have increased in response to the awareness campaign. Feedback has been received from local and overseas distributors, Canadian and American physicians and wearable medical and wellness device manufactures. Of note is that CardioComm Solutions' software technologies (GEMS™ WIN, GlobalCardio™, GEMS™ Home and GUAVA I/II) hold separate prescription use and over-the-counter ("OTC") clearances with Health Canada and the FDA as Class II medical devices, a differentiator from other medical software based organizations. Emerging biotech companies are recognizing that integration of their medical devices under CardioComm Solutions' established software medical license clearances will assist them in their efforts to secure their own clearance(s), increase the credibility of their products as health monitoring and wellness devices and reduce their cycle time/effort/cost to get to their products to market.
CardioComm Solutions also initiated a direct-to-pharmacist advertising campaign through the Rogers Healthcare Network (www.canadianhealthcarenetwork.ca) to promote:
- pharmacist awareness of the HeartCheck™ ECG PEN as an OTC product;
- pharmacist awareness of which patients would benefit from use of the HeartCheck™ ECG PEN; and
- the opportunity for pharmacists to offer ECG screening for arrhythmias & QT interval prolongation to their customers.
QT interval risk is associated with taking many prescribed medications and there remains a need to implement a system that can help assess risk from being prescribed such medications. Such option is now available through the HeartCheck™ ECG Screening Partner Program which will see use of the HeartCheck™ ECG PEN by pharmacists. The Roger Healthcare Network campaign has a focus on pharmacist education and is supported by pharmacist-specific material on the Company's HeartCheck™ website (www.theheartcheck.com).
The Company plans to continue with its structured campaigns to expand customer and investor awareness of its consumer and hospital biotechnology, health & wellness and heart monitoring innovations across a broader investor cross-section. To learn more about CardioComm Solutions' consumer HeartCheck™ ECG products and their hospital-based ambulatory cardiac arrhythmia technologies GEMS™ WIN, please see the Company's websites at www.theheartcheck.com and www.cardiocommsolutions.com.
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada.
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.